The Pharma Letter5d
Leqembi creator to work with Bristol Myers in $1.3 billion deal
Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...
조선일보5d
Seoul Asan Medical Center starts prescribing Alzheimer's drug Leqembi
Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...
pharmaphorum6d
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
Too Old to Operate6d
Year in Review – Alzheimer’s Disease
Lecanemab (Leqembi) and donanemab (Kisunla) have both received FDA approval as amyloid-beta targeting therapies.⁷⁻⁸ Several ...